$VolitionRX Ltd(VNRX)$ VolitionRX Ltd. (NYSE: VNRX) has published a new corporate presentation highlighting its focus on licensing its proprietary epigenetics-based diagnostic technologies targeting cancer and sepsis. The company reports a proven licensing model validated in the veterinary market, with multiple products already launched and a strong intellectual property portfolio consisting of 56 patent families and 71 granted patents with coverage up to 2044. The presentation outlines VolitionRX’s commercialization strategy, which is based on an asset-light business model leveraging commercial partnerships and out-licensing agreements. The approach includes upfront and milestone payments, recurring revenue from sales of key components, and royalties. VolitionRX is currently in confidential licensing discussions with about 10 large diagnostic and liquid biopsy companies worldwide, with initial agreements signed in the third quarter of 2025. Key markets addressed include multi-billion dollar opportunities in cancer screening, sepsis management, animal health, and research use. The company's platform is described as low-cost, scalable, and adaptable to various diagnostic workflows, with products ranging from manual to point-of-care tests. Projected catalysts include multiple licensing deals in 2025 and 2026, sales growth of CE-marked products in Europe, automation of tests, and adoption into national screening programs and routine clinical practice. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
